SI-BONE, Inc. SIBN
25.10 USD -0.50 (-1.95%)
At closeNov 10, 2026, 4:01 PM EST
25.10 0.00 0.00%
After hours · Nov 10, 4:01 PM ET
24.85 Day range 25.70
11.48 52-week range 25.92
- YTD
- +27.28%
- 1 year
- +60.08%
News
seekingalpha.com SI-BONE, Inc. (SIBN) Presents at 2026 UBS Global Healthcare Conference Transcript SI-BONE, Inc. (SIBN) Presents at 2026 UBS Global Healthcare Conference Transcript
zacks.com SiBone (SIBN) Hit a 52 Week High, Can the Run Continue? Si-Bone (SIBN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
benzinga.com TD Cowen Maintains Buy on SI-BONE, Raises Price Target to $23 TD Cowen analyst Mathew Blackman maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $20 to $23.
benzinga.com Needham Maintains Buy on SI-BONE, Lowers Price Target to $26 Needham analyst David Saxon maintains SI-BONE (NASDAQ:SIBN) with a Buy and lowers the price target from $27 to $26.
benzinga.com SI-BONE Q3 2026 Earnings Call Transcript SI-BONE (NASDAQ:SIBN) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com SI-BONE Affirms FY2026 Sales Guidance of $231.000M-$233.000M vs $232.024M Est SI-BONE (NASDAQ:SIBN) affirms FY2026 sales outlook from $231.000 million-$233.000 million to $231.000 million-$233.000 million vs $232.024 million estimate.
benzinga.com SI-BONE Q3 EPS $(0.08) Beats $(0.13) Estimate, Sales $55.704M Beat $55.404M Estimate SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.13) by 33.33 percent. This is a 27.27 percent increase over losses of $(0.11) per…
benzinga.com Truist Securities Maintains Buy on SI-BONE, Raises Price Target to $25 Truist Securities analyst Richard Newitter maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $23 to $25.
benzinga.com SI-BONE Receives FDA Clearance For Its iFuse Granite Onyx System SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced U.S. Food and Drug Administration…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals- benzinga.com Truist Securities Reiterates Buy on SI-BONE, Raises Price Target to $23 Truist Securities analyst Richard Newitter reiterates SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $21 to $23.
benzinga.com TD Cowen Maintains Buy on SI-BONE, Raises Price Target to $20 TD Cowen analyst Mathew Blackman maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $18 to $20.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $3.8 million. TransCode Therapeutics…- benzinga.com SI-BONE Raises FY2026 Sales Guidance from $230.000M-$233.000M to $231.000M-$233.000M vs $231.775M Est SI-BONE (NASDAQ:SIBN) raises FY2026 sales outlook from $230.000 million-$233.000 million to $231.000 million-$233.000 million vs $231.775 million estimate.
benzinga.com SI-BONE Q2 EPS $(0.09) Beats $(0.15) Estimate, Sales $56.010M Beat $55.335M Estimate SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.15) by 40 percent. This is a 35.71 percent increase over losses of $(0.14) per…- benzinga.com UBS Initiates Coverage On SI-BONE with Buy Rating, Announces Price Target of $24 UBS analyst Patrick Wood initiates coverage on SI-BONE (NASDAQ:SIBN) with a Buy rating and announces Price Target of $24.
- benzinga.com Truist Securities Maintains Buy on SI-BONE, Raises Price Target to $21 Truist Securities analyst Richard Newitter maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $18 to $21.
benzinga.com Zebra Technologies, Vishay Precision Group, Quantum Computing, Aramark And Other Big Stocks Moving Higher On Tuesday ZBRA, VSTS, AMBQ, VPG, BAK, PACS, LOT, EIKN, DDD, WEN, SIBN post significant gains on better-than-expected financial results and guidance. Peltz may take Wendy's private.- benzinga.com TD Cowen Maintains Buy on SI-BONE, Lowers Price Target to $18 TD Cowen analyst Mathew Blackman maintains SI-BONE (NASDAQ:SIBN) with a Buy and lowers the price target from $22 to $18.
- benzinga.com Truist Securities Reiterates Buy on SI-BONE, Lowers Price Target to $18 Truist Securities analyst Richard Newitter reiterates SI-BONE (NASDAQ:SIBN) with a Buy and lowers the price target from $20 to $18.
benzinga.com Why Harmonic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket Harmonic Inc (HLIT) rose in pre-market trading after beating earnings expectations & raising guidance. Other gainers include Buzzfeed, MacroGenics, & SI-Bone.- benzinga.com SI-BONE Raises FY2026 Sales Guidance from $228.500M-$232.500M to $230.000M-$233.000M vs $230.387M Est SI-BONE (NASDAQ:SIBN) raises FY2026 sales outlook from $228.500 million-$232.500 million to $230.000 million-$233.000 million vs $230.387 million estimate.
- benzinga.com SI-BONE Q1 EPS $(0.10) Beats $(0.18) Estimate, Sales $52.588M Beat $51.105M Estimate SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.18) by 44.44 percent. This is a 33.33 percent increase over losses of $(0.15) per…
benzinga.com Earnings Scheduled For May 11, 2026 - benzinga.com Truist Securities Maintains Buy on SI-BONE, Lowers Price Target to $20 Truist Securities analyst Samuel Brodovsky maintains SI-BONE (NASDAQ:SIBN) with a Buy and lowers the price target from $24 to $20.
- benzinga.com TD Cowen Maintains Buy on SI-BONE, Raises Price Target to $22 TD Cowen analyst Mathew Blackman maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $21 to $22.
- benzinga.com Truist Securities Reiterates Buy on SI-BONE, Raises Price Target to $24 Truist Securities analyst Richard Newitter reiterates SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $23 to $24.
benzinga.com SI-BONE Q4 Earnings Assessment - benzinga.com SI-BONE Q4 EPS $(0.04) Beats $(0.12) Estimate, Sales $56.350M Beat $55.397M Estimate SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.12) by 67.48 percent. This is a 63.64 percent increase over losses of $(0.11) per…
- benzinga.com Earnings Scheduled For February 23, 2026
benzinga.com A Look Ahead: SI-BONE's Earnings Forecast - benzinga.com A Glimpse Into The Expert Outlook On SI-BONE Through 5 Analysts
- benzinga.com TD Cowen Initiates Coverage On SI-BONE with Buy Rating, Announces Price Target of $21 TD Cowen analyst Mathew Blackman initiates coverage on SI-BONE (NASDAQ:SIBN) with a Buy rating and announces Price Target of $21.
- benzinga.com SI-BONE Reports Preliminary Q4 Global Revenue Between $56.2M - $56.3M, 2025 Global Revenue Between $200.8M - $200.9M SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced its preliminary and unaudited…
benzinga.com Why Did SI-Bone (SIBN) Surge Spike After Hours? SI-Bone shares rose in after-hours trading as three executives sold stock last week to cover RSU tax obligations.- benzinga.com Truist Securities Maintains Buy on SI-BONE, Raises Price Target to $23 Truist Securities analyst David Rescott maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $21 to $23.
- benzinga.com Canaccord Genuity Maintains Buy on SI-BONE, Raises Price Target to $27 Canaccord Genuity analyst Caitlin Roberts maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $26 to $27.
benzinga.com Accenture To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday 
benzinga.com Needham Maintains Buy on SI-BONE, Raises Price Target to $27 Needham analyst David Saxon maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $24 to $27.- benzinga.com Morgan Stanley Maintains Overweight on SI-BONE, Raises Price Target to $23 Morgan Stanley analyst Drew Ranieri maintains SI-BONE (NASDAQ:SIBN) with a Overweight and raises the price target from $20 to $23.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com SI-BONE Raises FY2025 Sales Guidance from $195.000M-$198.000M to $198.000M-$200.000M vs $196.584M Est SI-BONE (NASDAQ:SIBN) raises FY2025 sales outlook from $195.000 million-$198.000 million to $198.000 million-$200.000 million vs $196.584 million estimate.
- benzinga.com SI-BONE Q3 EPS $(0.11) Beats $(0.17) Estimate, Sales $48.656M Beat $46.667M Estimate SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.17) by 36.05 percent. This is a 31.25 percent increase over losses of $(0.16) per…
benzinga.com Earnings Scheduled For November 10, 2025 - benzinga.com Truist Securities Maintains Buy on SI-BONE, Lowers Price Target to $20 Truist Securities analyst David Rescott maintains SI-BONE (NASDAQ:SIBN) with a Buy and lowers the price target from $22 to $20.
benzinga.com Cantor Fitzgerald Reiterates Overweight on SI-BONE, Maintains $25 Price Target Cantor Fitzgerald analyst Ross Osborn reiterates SI-BONE (NASDAQ:SIBN) with a Overweight and maintains $25 price target.- benzinga.com SI-BONE Raises FY2025 Sales Guidance from $193.500M-$197.500M to $195.000M-$198.000M vs $195.834M Est SI-BONE (NASDAQ:SIBN) raises FY2025 sales outlook from $193.500 million-$197.500 million to $195.000 million-$198.000 million vs $195.834 million estimate.
- benzinga.com SI-BONE Q2 EPS $(0.14) Beats $(0.19) Estimate, Sales $48.630M Beat $48.112M Estimate SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.19) by 24.73 percent. This is a 36.36 percent increase over losses of $(0.22) per…
- benzinga.com Earnings Scheduled For August 4, 2025
- benzinga.com Truist Securities Maintains Buy on SI-BONE, Raises Price Target to $22 Truist Securities analyst Samuel Brodovsky maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $20 to $22.